VISTA Inhibitor Clinical Trials Market Size FDA Approval Patent Report 2025
First VISTA Inhibitor Drug Approval By 2028 Says Kuick Research In New Research Publication. Delhi, April 02, 2025 (GLOBE NEWSWIRE) -- Global VISTA Inhibitor Clini ...
BioWorld1d
Repare Therapeutics details discovery of PLK4 inhibitor RP-1664
The synthesis of RP-1664, a highly potent, selective and bioavailable PLK4 inhibitor for the potential treatment of cancer, was recently reported by Repare Therapeutics Inc.
The Manila Times6d
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...
The Manila Times6d
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
Durable complete response (CR) in a MCC patient treated with 15 mg/kg solnerstotug + cemiplimab. Patient continues on ...
EMBO Press6d
Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma
Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...